Japan Gout Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, and Others), By Disease Condition (Acute Gout and Chronic Gout), and Japan Gout Therapeutics Market Insights, Industry Trend, Forecasts to 2035
Industry: HealthcareJapan Gout Therapeutics Market Size Insights Forecasts to 2035
- The Japan Gout Therapeutics Market Size Was Estimated at USD 106.5 million in 2024
- The Market Size is Expected to Grow at a CAGR of Around 7.61 % from 2025 to 2035
- The Japan Gout Therapeutics Market Size is Expected to Reach USD 238.7 million by 2035
Get more details on this report -
According to a Research Report Published by Spherical Insights & Consulting, the Japan Gout Therapeutics Market Size is anticipated to reach USD 238.7 million by 2035, growing at a CAGR of 7.61 % from 2025 to 2035. The gout therapeutics market in Japan is driven by various factors, including rising prevalence of gout, advancements in treatment options, rising awareness about the disease, rising aging population, and unhealthy diets.
Market Overview
The gout therapeutics market focuses on the development, production, and sale of drugs which used to treat gout disease. Gout is the most frequent and complex type of inflammatory arthritis resulting from the accumulation of uric acid within the joints. It impacts men more often than women. The gout therapeutics include NSAIDs, corticosteroids, colchicine, and urate-lowering agents. Japan has one of the largest aging populations, and an aging population is more susceptible to lifestyle-related diseases like gout, which creates demand for more effective therapeutics. The people are becoming more aware of gout, and emerging treatments coupled with developments in telehealth and digital technology are facilitating patient compliance and fueling market expansion. The rising demand for personalized medicine is a key trend in this market. These trends present a significant opportunity for the development of personalized medicines based on an individual's genetic profile.
Report Coverage
This research report categorizes the market for the Japan gout therapeutics market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan gout therapeutics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan gout therapeutics market.
Japan Gout Therapeutics Market Report Coverage
Report Coverage | Details |
---|---|
Base Year: | 2024 |
Market Size in 2024: | USD 106.5 Million |
Forecast Period: | 2025-2035 |
Forecast Period CAGR 2025-2035 : | 7.61 % |
2035 Value Projection: | USD 238.7 Million |
Historical Data for: | 2020-2023 |
No. of Pages: | 159 |
Tables, Charts & Figures: | 130 |
Segments covered: | By Drug Class, By Disease Condition and COVID-19 Impact Analysis |
Companies covered:: | Takeda Pharmaceutical Company Limited, Teijin Pharma Ltd., Novartis AG, AstraZeneca K.K., Eisai Co., Ltd., FUJI YAKUHIN CO., LTD., Nippon Chemiphar Co., Ltd., Zydus Pharma Japan Co. Ltd., Merck & Co., Inc., GSK plc., and Other key vendors |
Pitfalls & Challenges: | COVID-19 Impact, Challenges, Future, Growth, & Analysis |
Get more details on this report -
Driving Factors
The rising prevalence of gout, especially among middle-aged and older adults due to lifestyle changes like poor dietary habits, obesity, and increased alcohol consumption, creates the demand for more effective treatments. The people are becoming aware of the lifestyle-related disorders, is further drives the market growth. Additionally, technical developments, emerging use modalities, and increasing awareness of the pathophysiology of disease also propel the market expansion.
Restraining Factors
The growth of Japan gout therapeutic market is hindered by several factors. One of the notable restraints is the high cost of advanced treatments, which may limit access for patients, especially those who have low incomes. Additionally, some gout medications lead to cardiovascular risks, which limit the market expansion.
Market Segmentation
The Japan gout therapeutics market share is classified into drug class and disease condition.
- The NSAIDs segment held the dominant share of the market in 2024 and is expected to grow at a rapid CAGR during the forecast period.
The Japan gout therapeutics market is segmented by drug class into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others. Among these, the NSAIDs segment held the dominant share in 2024 and is expected to grow at a rapid CAGR during the forecast period. This segmental growth is attributed to its low costs and high usage in combination therapy. Additionally, they are used as first-line treatment.
- The acute gout segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.
The Japan gout therapeutics market is segmented by disease condition into acute gout and chronic gout. Among these, the acute gout segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the high prevalence of acute gout attacks. Additionally, enhanced diagnostic tools and rising awareness contributed to the segmental growth.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan gout therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Takeda Pharmaceutical Company Limited
- Teijin Pharma Ltd.
- Novartis AG
- AstraZeneca K.K.
- Eisai Co., Ltd.
- FUJI YAKUHIN CO., LTD.
- Nippon Chemiphar Co., Ltd.
- Zydus Pharma Japan Co. Ltd.
- Merck & Co., Inc.
- GSK plc.
- Others
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan gout therapeutics market based on the below-mentioned segments:
Japan Gout Therapeutics Market, By Drug Class
- NSAIDs
- Corticosteroids
- Colchicine
- Urate-Lowering Agents
- Others
Japan Gout Therapeutics Market, By Disease Condition
- Acute Gout
- Chronic Gout
Need help to buy this report?